MCID: BRN028
MIFTS: 75

Brain Cancer

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Brain Cancer

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 11 53 14
Malignant Neoplasm of Brain 28 5 71 31
Adult Brain Tumor 11 53 71
Brain Neoplasms 75 43 71
Primary Malignant Neoplasm of Brain 11 71
Neoplasm of Brain 11 5
Brain Neoplasm 11 16
Brain Tumors 53 41
Malignant Primary Brain Neoplasm 11
Adult Malignant Brain Neoplasm 11
Malignant Tumor of Adult Brain 11
Malignant Primary Brain Tumors 53
Malignant Primary Brain Tumor 11
Malignant Tumor of Brain 11
Malignant Brain Tumour 11
Primary Brain Neoplasm 11
Brain Neoplasm, Adult 11
Primary Brain Tumors 14
Brain Tumor, Primary 71
Primary Brain Tumor 11
Brain Tumor Primary 53
Tumor of the Brain 11
Brain Tumor, Adult 19
Bt - Brain Tumour 11
Cancer, Brain 38

Classifications:



External Ids:

Disease Ontology 11 DOID:1319
ICD9CM 34 191 239.6
MeSH 43 D001932
ICD10 31 C71 C71.9
ICD11 33 1719389232
UMLS 71 C0006118 C0153633 C0220624 more

Summaries for Brain Cancer

MedlinePlus: 41 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are: Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack cancer cells with less harm to normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary: Brain Cancer, also known as malignant neoplasm of brain, is related to li-fraumeni syndrome and lung cancer, and has symptoms including tremor, back pain and headache. An important gene associated with Brain Cancer is MIR142 (MicroRNA 142), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Ropivacaine and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability

Disease Ontology: 11 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia: 75 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Related Diseases for Brain Cancer

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1173)
# Related Disease Score Top Affiliating Genes
1 li-fraumeni syndrome 32.9 TP53 PTEN PIK3CA IDH1 EGFR CTNNB1
2 lung cancer 32.6 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
3 medulloblastoma 32.6 TP53 PTPN11 PTEN PIK3CA NRAS MGMT
4 brain glioma 32.4 TP53 PTEN MGMT IDH2 IDH1 H3-3A
5 infratentorial cancer 32.4 TP53 PTEN MIR25 MIR142 MGMT IDH1
6 atypical teratoid rhabdoid tumor 32.4 TP53 MIR25 MIR142 IDH1 H3-3A EGFR
7 gliomatosis cerebri 32.3 TP53 PTEN MGMT IDH2 IDH1 H3-3A
8 glioblastoma 32.3 TP53 PTEN PIK3R1 PIK3CA NRAS MIR25
9 supratentorial cancer 32.2 TP53 MGMT IDH1 H3-3A
10 glioma susceptibility 1 32.0 TP53 IDH2 IDH1 H3-3A DANCR
11 papilloma 31.8 TP53 PTEN EGFR EGF
12 high grade glioma 31.7 TP53 PTEN PIK3CA MIR142 MGMT EGFR
13 glioma 31.7 TP53 PTEN PIK3CA MIR25 MGMT IDH2
14 brain stem glioma 31.7 TP53 PIK3CA IDH2 IDH1 H3-3A EGFR
15 adenocarcinoma 31.7 TP53 PTEN PIK3CA EGFR EGF CTNNB1
16 meningioma, familial 31.5 TP53 PTEN PIK3R1 PIK3CA MGMT IDH1
17 central nervous system cancer 31.3 TP53 MIR25 MIR142 MGMT IDH1 EGFR
18 cerebellar astrocytoma 31.3 IDH1 H3-3A BRAF
19 lynch syndrome 31.3 TP53 PTEN PIK3R1 PIK3CA MGMT IDH1
20 neuroblastoma 31.2 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
21 oligodendroglioma 31.2 TP53 PTEN MGMT IDH2 IDH1 EGFR
22 low grade glioma 31.2 TP53 PTEN MIR142 MGMT IDH2 IDH1
23 kidney cancer 31.2 TP53 PIK3CA MIR142 EGFR EGF
24 giant cell glioblastoma 31.2 TP53 PTEN PIK3R1 PIK3CA NRAS MGMT
25 pilocytic astrocytoma 31.1 TP53 PTPN11 PTEN NRAS MGMT IDH2
26 central nervous system benign neoplasm 31.1 TP53 PTEN MIR142 MGMT IDH2 IDH1
27 familial adenomatous polyposis 31.1 TP53 MGMT CTNNB1 BRAF
28 squamous cell carcinoma 31.1 TP53 PTEN PIK3CA NRAS EGFR EGF
29 juvenile pilocytic astrocytoma 31.1 TP53 IDH1 H3-3A
30 noonan syndrome 1 31.1 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
31 lipomatosis, multiple 31.0 TP53 PTEN PIK3CA
32 pleomorphic xanthoastrocytoma 31.0 TP53 MGMT IDH2 IDH1 H3-3A BRAF
33 small cell carcinoma 31.0 TP53 PTEN EGFR ALK
34 rectal benign neoplasm 31.0 TP53 PIK3CA EGFR CTNNB1
35 gemistocytic astrocytoma 31.0 TP53 PTEN MGMT IDH2 IDH1
36 anaplastic astrocytoma 31.0 TP53 PTEN MGMT IDH2 IDH1 H3-3A
37 endometrial cancer 31.0 TP53 PTEN PIK3R1 PIK3CA NRAS MGMT
38 pilomyxoid astrocytoma 31.0 MGMT IDH2 IDH1 H3-3A BRAF
39 mismatch repair cancer syndrome 31.0 TP53 PTEN PIK3CA MGMT CTNNB1
40 spinal cord disease 31.0 TP53 PTEN MIR142 MGMT IDH2 IDH1
41 frontal lobe neoplasm 31.0 TP53 MGMT IDH1 EGFR
42 fibrillary astrocytoma 31.0 TP53 IDH2 IDH1 H3-3A
43 skin melanoma 31.0 TP53 PTEN PIK3R1 PIK3CA NRAS IDH1
44 cerebral ventricle cancer 31.0 TP53 MGMT IDH1 H3-3A
45 breast cancer 30.9 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
46 cholangiocarcinoma 30.9 TP53 PTEN PIK3CA IDH2 IDH1 EGFR
47 myelodysplastic syndrome 30.9 TP53 PTPN11 NRAS MIR142 IDH2 IDH1
48 lung cancer susceptibility 3 30.9 TP53 PTPN11 PIK3CA NRAS MIR25 MIR142
49 intrahepatic cholangiocarcinoma 30.9 TP53 MIR142 IDH2 IDH1 EGFR CTNNB1
50 leukemia, chronic lymphocytic 30.9 TP53 PTPN11 PTEN NRAS MIR142 EGFR

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Impaired Intellectual Development Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer

Symptoms & Phenotypes for Brain Cancer

UMLS symptoms related to Brain Cancer:


tremor; back pain; headache; syncope; pain; chronic pain; sciatica; seizures; vertigo/dizziness; sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

25 (show top 50) (show all 56)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.43 PIK3R1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.43 IDH1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.43 BIRC6
4 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.43 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.43 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.43 EGFR
7 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.43 IDH1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.43 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.43 IDH1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.43 IDH1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.43 BRAF
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.43 BIRC6 IDH2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.43 TP53
14 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.43 IDH1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.43 IDH2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.43 IDH2 PIK3R1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.43 PTPN11
18 Increased shRNA abundance (Z-score > 2) GR00366-A-18 10.43 IDH1 BIRC6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-181 10.43 BIRC6
20 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.43 TP53 BIRC6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.43 TP53
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.43 TP53
23 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.43 IDH2 PIK3R1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-20 10.43 TP53
25 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.43 BIRC6
26 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.43 EGFR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.43 EGFR PIK3R1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-216 10.43 IDH2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.43 BIRC6
30 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.43 IDH2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.43 PIK3R1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.43 TP53
33 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.43 TP53 IDH1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.43 IDH2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.43 EGFR PIK3R1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.43 BRAF CTNNB1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.43 PIK3CA
38 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10.43 TP53
39 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.43 PTPN11
40 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.43 IDH2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.43 PTPN11
42 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.43 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.43 BIRC6
44 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.43 EGFR
45 Decreased viability GR00055-A-1 10.25 EGFR PIK3CA
46 Decreased viability GR00055-A-2 10.25 EGFR PIK3CA
47 Decreased viability GR00221-A-1 10.25 ALK EGFR NRAS PIK3CA PIK3R1
48 Decreased viability GR00221-A-2 10.25 PIK3CA
49 Decreased viability GR00221-A-3 10.25 NRAS PIK3R1
50 Decreased viability GR00221-A-4 10.25 ALK EGFR PIK3CA

MGI Mouse Phenotypes related to Brain Cancer:

45 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.42 ALK BRAF CTNNB1 DANCR EGFR IDH2
2 homeostasis/metabolism MP:0005376 10.42 ALK BIRC6 BRAF CTNNB1 DANCR EGFR
3 normal MP:0002873 10.38 ALK BIRC6 BRAF CTNNB1 EGF EGFR
4 growth/size/body region MP:0005378 10.38 ALK BIRC6 BRAF CTNNB1 EGF EGFR
5 nervous system MP:0003631 10.37 ALK BIRC6 BRAF CTNNB1 EGFR IDH1
6 endocrine/exocrine gland MP:0005379 10.34 ALK BIRC6 BRAF CTNNB1 EGF EGFR
7 cellular MP:0005384 10.29 ACRBP BIRC6 BRAF CTNNB1 EGFR H3-3A
8 immune system MP:0005387 10.28 BIRC6 BRAF CTNNB1 EGF EGFR IDH1
9 liver/biliary system MP:0005370 10.27 BIRC6 BRAF CTNNB1 DANCR EGFR NRAS
10 pigmentation MP:0001186 10.22 ALK BRAF CTNNB1 EGFR NRAS PTEN
11 embryo MP:0005380 10.21 BIRC6 BRAF CTNNB1 EGFR H3-3A NRAS
12 cardiovascular system MP:0005385 10.2 BIRC6 BRAF CTNNB1 EGFR IDH2 NRAS
13 muscle MP:0005369 10.19 BRAF CTNNB1 EGFR PIK3CA PIK3R1 PTEN
14 digestive/alimentary MP:0005381 10.15 BRAF CTNNB1 EGF EGFR NRAS PIK3CA
15 no phenotypic analysis MP:0003012 10.14 CTNNB1 EGFR MGMT NRAS PIK3CA PTPN11
16 limbs/digits/tail MP:0005371 10.11 BRAF CTNNB1 EGFR NRAS PTEN PTPN11
17 reproductive system MP:0005389 10.11 ACRBP ALK BRAF CTNNB1 EGF EGFR
18 adipose tissue MP:0005375 10.1 BRAF EGFR PIK3CA PIK3R1 PTEN PTPN11
19 respiratory system MP:0005388 10.06 ALK BRAF CTNNB1 EGFR IDH1 MGMT
20 skeleton MP:0005390 10.06 ALK BRAF CTNNB1 EGFR IDH1 IDH2
21 vision/eye MP:0005391 10 ALK BRAF CTNNB1 EGF EGFR NRAS
22 hematopoietic system MP:0005397 9.93 BIRC6 BRAF CTNNB1 EGFR IDH1 IDH2
23 mortality/aging MP:0010768 9.83 ALK BIRC6 BRAF CTNNB1 EGFR H3-3A
24 integument MP:0010771 9.4 ALK BIRC6 BRAF CTNNB1 EGF EGFR

Drugs & Therapeutics for Brain Cancer

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 542)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
4
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
6
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
7
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
8
Phenylephrine Approved Phase 4 59-42-7 6041
9
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
12
Labetalol Approved Phase 4 36894-69-6 3869
13
Hydralazine Approved Phase 4 86-54-4 3637
14
Clevidipine Approved, Investigational Phase 4 167221-71-8 153994
15
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
16
Levetiracetam Approved Phase 4 102767-28-2 441341 5284583
17
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
18
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
19
Donepezil Approved Phase 4 120014-06-4 3152
20
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
21
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
22
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
23
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
24
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
25
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
26
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537 59227
27
Amitriptyline Approved Phase 4 50-48-6 2160
28
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
29
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
30
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
31
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
32
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
33
Pramipexole Approved, Investigational Phase 4 104632-26-0, 104632-25-9, 104632-28-2 4885 119570 59868
34
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 60857
35
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
36
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
37
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
38
Topiramate Approved Phase 4 97240-79-4 5284627
39
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
40
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
41 Bronchodilator Agents Phase 4
42 Adrenergic beta-Agonists Phase 4
43 Central Nervous System Stimulants Phase 4
44 Analgesics, Opioid Phase 4
45 Narcotics Phase 4
46 Adrenergic alpha-Agonists Phase 4
47 Adrenergic Agonists Phase 4
48 Adrenergic Agents Phase 4
49 Dopamine Uptake Inhibitors Phase 4
50 Cytochrome P-450 Enzyme Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 1564)
# Name Status NCT ID Phase Drugs
1 Effects of Pre-emptive Scalp Infiltration With Ketorolac and Ropivacaine for Postoperative Pain Relief After Elective Supratentorial Craniotomy (PAINLESS) Unknown status NCT04141319 Phase 4 Ketorolac;Ropivacaine;Epinephrine
2 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
3 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
4 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
5 A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors Completed NCT00075166 Phase 4
6 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide
7 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial Completed NCT02334722 Phase 4 Levetiracetam
8 The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
9 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Completed NCT02964416 Phase 4 Injection Tramadol
10 Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors Completed NCT02713087 Phase 4 Ephedrine;Phenylephrine
11 The Effect of Pre-incisional Anterior Scalp Block on Intraoperative Opioid Consumption in Adult Patients Undergoing Elective Craniotomy to Remove Tumor: A Prospective Randomized Controlled Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
12 Effective and Safe Morphine Dose for Patient Controlled Anesthesia in Supratentorial Craniotomies Completed NCT04313374 Phase 4 Morphine PCA 1 mg;Morphine PCA 0,5 mg;Placebo
13 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block: A Randomized Controlled Trial Completed NCT02558569 Phase 4 Levobupivacaine
14 Validation and Verification of 3 Dimensional Laparoscopic System in Laparoscopic Distal Pancreatectomy & Splenectomy Completed NCT02757690 Phase 4
15 A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
16 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Completed NCT04266665 Phase 4 Dexmedetomidine
17 The Effect of Intravenous Single Dose of Magnesium Sulphate on Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application During Craniotomies Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
18 Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study Completed NCT02708056 Phase 4 Sugammadex
19 Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
20 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
21 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
22 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
23 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
24 Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study) Completed NCT00571155 Phase 4 levetiracetam
25 A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer Treated With Pyrrolidine Maleate and Capecitabine Combined With Brain Radiotherapy Recruiting NCT04767828 Phase 4 PYRROTINI
26 A Pilot Study of Dual Time Point FDG PET MR Imaging Optimization for the Evaluation of Brain Metastasis Recruiting NCT05054998 Phase 4
27 Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Craniotomy for Primary Brain Tumors Recruiting NCT05141877 Phase 4 Propofol;Sevoflurane
28 Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy Recruiting NCT05202899 Phase 4 sugammadex
29 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
30 Phase IV GliaSite® Radiation Therapy System Registry Protocol for the Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
31 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
32 Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of AZD9291 in Brain Metastases From Patients With EGFR T790M Positive NSCLC Who Have Received Prior Therapy With an EGFR-TKI Unknown status NCT02972333 Phase 3 AZD9291 80mg oral each day
33 Hypofractionated Radiotherapy With Concurrent Temozolomide for Large Brain Metastases: a Multi-center Randomized Phase III Trial Unknown status NCT03778541 Phase 3 Temozolomide
34 Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures Unknown status NCT02563288 Phase 3 Esmolol;Dexmedetomidine
35 Whole Brain Radiotherapy Concurrent With EGFR-TKI Versus EGFR-TKI Alone in the Treatment of Non-small Cell Lung Cancer Patients With Brain Metastasis Unknown status NCT02714010 Phase 3 EGFR-TKI
36 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
37 A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis Unknown status NCT02460068 Phase 3 Fotemustine;Fotemustine and Ipilimumab;Ipilimumab and nivolumab
38 A Phase III Trial Comparing Whole Brain Radiation (WBRT) and Stereotactic Radiosurgery (SRS) Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases Unknown status NCT00268684 Phase 3 Erlotinib, Temozolomide
39 Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial Unknown status NCT02338011 Phase 2, Phase 3 Gefitinib
40 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
41 Comparing Whole Brain Radiation With Hypofractionated Stereotactic RadioSurgery (HFSRS) in Patients With NSCL Brain Metastases Unknown status NCT02882984 Phase 3 Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib
42 Proteome-based Personalized Immunotherapy of Brain Metastases From Breast Cancer Unknown status NCT01782274 Phase 2, Phase 3
43 A Randomized Trial of Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases Unknown status NCT01353573 Phase 3
44 Proteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer Unknown status NCT01782287 Phase 2, Phase 3
45 Phase 3 Study of Stereotactic Radiotherapy of the Postoperative Resection Cavity Versus Whole-Brain Irradiation After Surgical Resection of Single Brain Metastasis Unknown status NCT01535209 Phase 3
46 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
47 Proteome-based Personalized Immunotherapy of Malignant Brain Tumors Unknown status NCT01759810 Phase 2, Phase 3
48 Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor Completed NCT00681551 Phase 3 Magnevist (SH L 451A)
49 To Determine Which of Two Radiotherapy Brain Fractionation Schemes is Superior in the Treatment of Brain Metastases Completed NCT00138788 Phase 3
50 Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504) Completed NCT00280475 Phase 3

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Etoposide
etoposide phosphate
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
Mifepristone
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: brain neoplasms

Genetic Tests for Brain Cancer

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Malignant Neoplasm of Brain 28

Anatomical Context for Brain Cancer

Organs/tissues related to Brain Cancer:

MalaCards : Brain, Breast, Lung, Eye, T Cells, Bone Marrow, Cortex

Publications for Brain Cancer

Articles related to Brain Cancer:

(show top 50) (show all 33839)
# Title Authors PMID Year
1
PTEN controls tumor-induced angiogenesis. 62 5
11274365 2001
2
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
3
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
4
Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients. 5
24721394 2014
5
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. 5
23558169 2013
6
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. 5
22586120 2012
7
Targeted therapy for BRAFV600E malignant astrocytoma. 5
22038996 2011
8
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. 5
22072639 2011
9
Survey of MicroRNA expression in pediatric brain tumors. 62 46
21157891 2011
10
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. 5
17177598 2006
11
Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial. 41
36322102 2022
12
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases. 41
36170791 2022
13
Effect of low-dose lidocaine on MEPs in patients undergoing intracranial tumor resection with propofol anesthesia: A randomized controlled trial. 41
35960044 2022
14
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. 53 62
20516477 2010
15
Inhibition of tubulogenesis and of carcinogen-mediated signaling in brain endothelial cells highlight the antiangiogenic properties of a mumbaistatin analog. 53 62
20486934 2010
16
FasL gene knock-down therapy enhances the antiglioma immune response. 53 62
20406899 2010
17
Seizures in low- and high-grade gliomas: current management and future outlook. 53 62
20469999 2010
18
Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors. 53 62
19779861 2010
19
Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. 53 62
20133820 2010
20
Mig-6 controls EGFR trafficking and suppresses gliomagenesis. 53 62
20351267 2010
21
The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. 53 62
20360385 2010
22
Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival. 53 62
20175962 2010
23
Promising human brain tumors therapy with interference RNA intervention (iRNAi). 53 62
20118657 2010
24
Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro. 53 62
19884327 2010
25
Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. 53 62
19856393 2010
26
Changes of AXIN-1 and beta-catenin in neuroepithelial brain tumors. 53 62
19633924 2010
27
MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. 53 62
20152724 2010
28
CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data. 53 62
20031968 2010
29
Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. 53 62
19756596 2010
30
Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors. 53 62
19588228 2009
31
Differential expression of Notch family members in astrocytomas and medulloblastomas. 53 62
19424825 2009
32
Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome. 53 62
20017945 2009
33
5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines. 53 62
19919819 2009
34
Magnetic resonance perfusion and permeability imaging in brain tumors. 53 62
19959004 2009
35
VEGF inhibitors in brain tumors. 53 62
20075834 2009
36
Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling. 53 62
19326372 2009
37
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. 53 62
19724855 2009
38
Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. 53 62
19633684 2009
39
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. 53 62
19535798 2009
40
A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. 53 62
19689300 2009
41
[Common mechanism underlying oligodendrocyte development and oligodendrogliomagenesis]. 53 62
19618851 2009
42
BMI1 sustains human glioblastoma multiforme stem cell renewal. 53 62
19605626 2009
43
[AQP4 expression in the brains of patients with glioblastoma and its association with brain edema]. 53 62
19764565 2009
44
Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. 53 62
19602687 2009
45
Proteomic and immunologic analyses of brain tumor exosomes. 53 62
19109410 2009
46
Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. 53 62
19439100 2009
47
Eukaryotic initiation factors (eIF) 2alpha and 4E expression, localization, and phosphorylation in brain tumors. 53 62
19188486 2009
48
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. 53 62
19333229 2009
49
Expression of iron-related genes in human brain and brain tumors. 53 62
19386095 2009
50
Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. 53 62
19276162 2009

Variations for Brain Cancer

ClinVar genetic disease variations for Brain Cancer:

5 (show top 50) (show all 240)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 EGFR NM_005228.5(EGFR):c.865_866delinsAT (p.Ala289Ile) INDEL Likely Pathogenic
376398 rs1057519887 GRCh37: 7:55221821-55221822
GRCh38: 7:55154128-55154129
2 PIK3R1 NM_181523.3(PIK3R1):c.1126G>C (p.Gly376Arg) SNV Likely Pathogenic
376065 rs1057519757 GRCh37: 5:67589138-67589138
GRCh38: 5:68293310-68293310
3 EGFR NM_005228.5(EGFR):c.1793G>C (p.Gly598Ala) SNV Likely Pathogenic
376399 rs139236063 GRCh37: 7:55233043-55233043
GRCh38: 7:55165350-55165350
4 EGFR NM_005228.5(EGFR):c.866C>T (p.Ala289Val) SNV Likely Pathogenic
376209 rs149840192 GRCh37: 7:55221822-55221822
GRCh38: 7:55154129-55154129
5 EGFR NM_005228.5(EGFR):c.866C>A (p.Ala289Asp) SNV Likely Pathogenic
376396 rs149840192 GRCh37: 7:55221822-55221822
GRCh38: 7:55154129-55154129
6 CTNNB1 NM_001904.4(CTNNB1):c.133T>G (p.Ser45Ala) SNV Likely Pathogenic
376241 rs121913407 GRCh37: 3:41266136-41266136
GRCh38: 3:41224645-41224645
7 EGFR NM_005228.5(EGFR):c.323G>A (p.Arg108Lys) SNV Likely Pathogenic
376207 rs1057519828 GRCh37: 7:55211080-55211080
GRCh38: 7:55143387-55143387
8 EGFR NM_005228.5(EGFR):c.865G>A (p.Ala289Thr) SNV Likely Pathogenic
376395 rs769696078 GRCh37: 7:55221821-55221821
GRCh38: 7:55154128-55154128
9 EGFR NM_005228.5(EGFR):c.1793G>T (p.Gly598Val) SNV Likely Pathogenic
376210 rs139236063 GRCh37: 7:55233043-55233043
GRCh38: 7:55165350-55165350
10 EGFR NM_005228.5(EGFR):c.322A>G (p.Arg108Gly) SNV Likely Pathogenic
376400 rs1057519888 GRCh37: 7:55211079-55211079
GRCh38: 7:55143386-55143386
11 EGFR NM_005228.5(EGFR):c.865_866delinsAA (p.Ala289Asn) INDEL Likely Pathogenic
376397 rs1057519887 GRCh37: 7:55221821-55221822
GRCh38: 7:55154128-55154129
12 ACRBP NM_032489.3(ACRBP):c.1040dup (p.Tyr348fs) DUP Risk Factor
984953 rs1949067963 GRCh37: 12:6752741-6752742
GRCh38: 12:6643575-6643576
13 PTPN11 NM_002834.5(PTPN11):c.215C>A (p.Ala72Asp) SNV Likely Pathogenic
376511 rs121918454 GRCh37: 12:112888199-112888199
GRCh38: 12:112450395-112450395
14 ALK NM_004304.5(ALK):c.3575G>C (p.Arg1192Pro) SNV Likely Pathogenic
18085 rs113994089 GRCh37: 2:29443642-29443642
GRCh38: 2:29220776-29220776
15 ALK NM_004304.5(ALK):c.3383G>C (p.Gly1128Ala) SNV Likely Pathogenic
18084 rs113994088 GRCh37: 2:29445450-29445450
GRCh38: 2:29222584-29222584
16 PIK3CA NM_006218.4(PIK3CA):c.1359A>T (p.Glu453Asp) SNV Likely Pathogenic
376472 rs1057519926 GRCh37: 3:178928081-178928081
GRCh38: 3:179210293-179210293
17 PIK3CA NM_006218.4(PIK3CA):c.1637A>C (p.Gln546Pro) SNV Likely Pathogenic
375898 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
18 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely Pathogenic
217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
19 IDH1 NM_005896.4(IDH1):c.394C>G (p.Arg132Gly) SNV Likely Pathogenic
375892 rs121913499 GRCh37: 2:209113113-209113113
GRCh38: 2:208248389-208248389
20 PIK3CA NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys) SNV Likely Pathogenic
13657 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
21 IDH1 NM_005896.4(IDH1):c.394C>A (p.Arg132Ser) SNV Likely Pathogenic
375893 rs121913499 GRCh37: 2:209113113-209113113
GRCh38: 2:208248389-208248389
22 PIK3CA NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu) SNV Likely Pathogenic
375899 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
23 PIK3CA NM_006218.4(PIK3CA):c.1638G>T (p.Gln546His) SNV Likely Pathogenic
376491 rs1057519940 GRCh37: 3:178936096-178936096
GRCh38: 3:179218308-179218308
24 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Likely Pathogenic
13653 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
25 IDH1 NM_005896.4(IDH1):c.394C>T (p.Arg132Cys) SNV Likely Pathogenic
375891 rs121913499 GRCh37: 2:209113113-209113113
GRCh38: 2:208248389-208248389
26 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Likely Pathogenic
39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
27 PIK3CA NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp) SNV Likely Pathogenic
156446 rs587777790 GRCh37: 3:178917478-178917478
GRCh38: 3:179199690-179199690
28 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
29 IDH2 NM_002168.4(IDH2):c.514A>G (p.Arg172Gly) SNV Likely Pathogenic
376439 rs1057519906 GRCh37: 15:90631839-90631839
GRCh38: 15:90088607-90088607
30 IDH2 NM_002168.4(IDH2):c.514A>T (p.Arg172Trp) SNV Likely Pathogenic
376438 rs1057519906 GRCh37: 15:90631839-90631839
GRCh38: 15:90088607-90088607
31 IDH2 NM_002168.4(IDH2):c.515G>A (p.Arg172Lys) SNV Likely Pathogenic
375987 rs121913503 GRCh37: 15:90631838-90631838
GRCh38: 15:90088606-90088606
32 IDH2 NM_002168.4(IDH2):c.515G>T (p.Arg172Met) SNV Likely Pathogenic
375986 rs121913503 GRCh37: 15:90631838-90631838
GRCh38: 15:90088606-90088606
33 PIK3CA NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile) SNV Likely Pathogenic
179173 rs121913283 GRCh37: 3:178952074-178952074
GRCh38: 3:179234286-179234286
34 TP53 NM_000546.6(TP53):c.731G>T (p.Gly244Val) SNV Likely Pathogenic
376601 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
35 TP53 NM_000546.6(TP53):c.730G>C (p.Gly244Arg) SNV Likely Pathogenic
376602 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
36 TP53 NM_000546.6(TP53):c.403T>A (p.Cys135Ser) SNV Likely Pathogenic
376562 rs1057519975 GRCh37: 17:7578527-7578527
GRCh38: 17:7675209-7675209
37 TP53 NM_000546.6(TP53):c.824G>T (p.Cys275Phe) SNV Likely Pathogenic
376582 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
38 TP53 NM_000546.6(TP53):c.821T>A (p.Val274Asp) SNV Likely Pathogenic
376675 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799
39 TP53 NM_000546.6(TP53):c.395A>T (p.Lys132Met) SNV Likely Pathogenic
376629 rs1057519996 GRCh37: 17:7578535-7578535
GRCh38: 17:7675217-7675217
40 TP53 NM_000546.6(TP53):c.810T>G (p.Phe270Leu) SNV Likely Pathogenic
376595 rs1057519987 GRCh37: 17:7577128-7577128
GRCh38: 17:7673810-7673810
41 TP53 NM_000546.6(TP53):c.584T>G (p.Ile195Ser) SNV Likely Pathogenic
376619 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
42 TP53 NM_000546.6(TP53):c.722C>A (p.Ser241Tyr) SNV Likely Pathogenic
376663 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
43 TP53 NM_000546.6(TP53):c.452C>G (p.Pro151Arg) SNV Likely Pathogenic
376640 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
44 TP53 NM_000546.6(TP53):c.373A>C (p.Thr125Pro) SNV Likely Pathogenic
376666 rs1057520003 GRCh37: 17:7579314-7579314
GRCh38: 17:7675996-7675996
45 TP53 NM_000546.6(TP53):c.452C>A (p.Pro151His) SNV Likely Pathogenic
376639 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
46 TP53 NM_000546.6(TP53):c.581T>C (p.Leu194Pro) SNV Likely Pathogenic
376635 rs1057519998 GRCh37: 17:7578268-7578268
GRCh38: 17:7674950-7674950
47 TP53 NM_000546.6(TP53):c.809T>G (p.Phe270Cys) SNV Likely Pathogenic
376597 rs1057519986 GRCh37: 17:7577129-7577129
GRCh38: 17:7673811-7673811
48 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys) SNV Likely Pathogenic
376470 rs1057519925 GRCh37: 3:178928079-178928079
GRCh38: 3:179210291-179210291
49 TP53 NM_000546.6(TP53):c.577C>G (p.His193Asp) SNV Likely Pathogenic
376613 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
50 TP53 NM_000546.6(TP53):c.614A>C (p.Tyr205Ser) SNV Likely Pathogenic
376683 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917

Copy number variations for Brain Cancer from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 112045 17 37800000 41900000 Gain Brain cancer
2 179187 8 123863081 124055936 Deletion RAF1 Brain cancer
3 205638 6 130400000 131300000 Deletion Brain cancer
4 233881 8 128747764 129113498 Amplification MYC Brain cancer
5 234173 8 131500000 139900000 Amplification KHDRBS3 Brain cancer
6 254105 9 51800000 140273252 Deletion Brain cancer

Expression for Brain Cancer

Search GEO for disease gene expression data for Brain Cancer.

Pathways for Brain Cancer

Pathways related to Brain Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 TP53 PTEN PIK3R1 NRAS H3-3A EGFR
2 13.85 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
3
Show member pathways
13.79 ALK BIRC6 BRAF CTNNB1 EGF EGFR
4
Show member pathways
13.66 ALK BRAF CTNNB1 EGF EGFR H3-3A
5
Show member pathways
13.64 ALK BRAF EGF EGFR H3-3A NRAS
6
Show member pathways
13.52 PTEN PIK3R1 PIK3CA NRAS EGFR EGF
7
Show member pathways
13.5 TP53 PTEN PIK3R1 NRAS EGFR EGF
8
Show member pathways
13.45 BRAF CTNNB1 EGF EGFR H3-3A MGMT
9
Show member pathways
13.4 PTPN11 PTEN PIK3R1 NRAS EGFR EGF
10
Show member pathways
13.4 EGF H3-3A NRAS PIK3CA PIK3R1 PTPN11
11
Show member pathways
13.4 ALK BIRC6 BRAF CTNNB1 EGF EGFR
12
Show member pathways
13.38 PIK3R1 NRAS EGFR EGF CTNNB1 BRAF
13
Show member pathways
13.18 EGF EGFR PIK3CA PIK3R1 PTEN PTPN11
14
Show member pathways
13.18 TP53 PTEN PIK3R1 NRAS EGFR EGF
15
Show member pathways
13.09 EGF EGFR H3-3A NRAS PIK3CA PIK3R1
16
Show member pathways
13.06 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
17
Show member pathways
13.02 EGF EGFR PIK3CA PIK3R1 PTEN TP53
18
Show member pathways
12.98 BRAF EGFR NRAS PIK3CA PIK3R1 PTEN
19
Show member pathways
12.97 PIK3R1 PIK3CA NRAS CTNNB1 BRAF
20
Show member pathways
12.97 BRAF NRAS PIK3CA PIK3R1 PTEN PTPN11
21
Show member pathways
12.94 TP53 PIK3R1 PIK3CA NRAS BRAF
22
Show member pathways
12.94 PIK3R1 PIK3CA NRAS EGFR BRAF
23
Show member pathways
12.93 BRAF CTNNB1 NRAS PIK3CA PIK3R1
24
Show member pathways
12.86 PTPN11 PTEN PIK3R1 PIK3CA EGFR EGF
25 12.81 TP53 PTEN PIK3CA EGFR EGF CTNNB1
26
Show member pathways
12.8 PTPN11 PTEN PIK3R1 PIK3CA EGFR EGF
27
Show member pathways
12.79 PIK3R1 NRAS EGFR EGF BRAF
28
Show member pathways
12.79 PIK3R1 NRAS EGFR EGF CTNNB1 BRAF
29
Show member pathways
12.78 TP53 PIK3R1 NRAS EGFR EGF BRAF
30
Show member pathways
12.75 TP53 PTPN11 PIK3R1 PIK3CA NRAS EGFR
31 12.74 ALK BRAF CTNNB1 EGF EGFR NRAS
32
Show member pathways
12.7 PTPN11 PIK3R1 PIK3CA NRAS BRAF
33
Show member pathways
12.69 TP53 PTPN11 PIK3R1 PIK3CA NRAS EGFR
34
Show member pathways
12.67 PTPN11 PIK3R1 PIK3CA NRAS BRAF
35
Show member pathways
12.55 PIK3R1 PIK3CA NRAS EGFR EGF
36
Show member pathways
12.55 CTNNB1 EGFR NRAS PIK3CA PIK3R1 TP53
37 12.53 TP53 NRAS EGFR EGF BRAF
38
Show member pathways
12.53 PTPN11 PIK3R1 PIK3CA CTNNB1 BRAF
39
Show member pathways
12.53 TP53 PTPN11 PTEN PIK3R1 PIK3CA CTNNB1
40
Show member pathways
12.52 PTPN11 PIK3R1 PIK3CA NRAS EGFR EGF
41
Show member pathways
12.51 PTPN11 PIK3R1 PIK3CA NRAS
42
Show member pathways
12.51 PTPN11 PIK3R1 PIK3CA NRAS
43
Show member pathways
12.49 PTPN11 PIK3R1 PIK3CA CTNNB1
44
Show member pathways
12.47 ALK BRAF CTNNB1 EGF EGFR NRAS
45
Show member pathways
12.45 PTPN11 PTEN PIK3R1 PIK3CA NRAS
46
Show member pathways
12.45 PIK3R1 PIK3CA NRAS EGFR EGF CTNNB1
47
Show member pathways
12.44 PIK3CA PIK3R1 PTEN PTPN11
48
Show member pathways
12.43 PIK3R1 PIK3CA EGFR EGF
49
Show member pathways
12.42 CTNNB1 NRAS PIK3CA PIK3R1
50
Show member pathways
12.41 PIK3CA PIK3R1 PTPN11 TP53

GO Terms for Brain Cancer

Cellular components related to Brain Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.44 TP53 PTPN11 PIK3R1 H3-3A EGFR CTNNB1

Biological processes related to Brain Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 10.06 NRAS EGFR CTNNB1 BRAF
2 negative regulation of apoptotic process GO:0043066 10.06 TP53 PTEN PIK3R1 MGMT EGFR CTNNB1
3 phosphatidylinositol 3-kinase signaling GO:0014065 9.88 PTEN PIK3R1 PIK3CA
4 T cell differentiation in thymus GO:0033077 9.85 TP53 CTNNB1 BRAF
5 positive regulation of protein tyrosine kinase activity GO:0061098 9.83 EGFR EGF ALK
6 cell population proliferation GO:0008283 9.8 BIRC6 CTNNB1 EGF EGFR PTEN TP53
7 isocitrate metabolic process GO:0006102 9.78 IDH2 IDH1
8 glyoxylate cycle GO:0006097 9.62 IDH2 IDH1
9 regulation of cell population proliferation GO:0042127 9.61 TP53 EGFR CTNNB1 BRAF BIRC6 ALK
10 positive regulation of miRNA maturation GO:1903800 9.51 TP53 EGFR
11 regulation of axon regeneration GO:0048679 9.49 PTEN BRAF
12 epidermal growth factor receptor signaling pathway GO:0007173 9.32 PTPN11 PIK3CA EGFR EGF BRAF

Molecular functions related to Brain Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.56 TP53 PIK3R1 EGFR CTNNB1
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.92 IDH2 IDH1

Sources for Brain Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....